FDA places partial clinical hold on Nurix's NX-2127 Phase 1 trial; enrollment paused

Nurix Therapeutics, Inc.

FDA partial clinical hold on U.S. Phase 1 study NX-2127-001 for B-cell malignancies; screening and enrollment paused.
Patients currently enrolled who derive clinical benefit may continue treatment per ongoing protocol.
Hold follows Nurix's communication to FDA of intention to transition to an improved manufacturing process.
Nurix's other drug programs are not affected by the NX-2127 manufacturing process improvement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.